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R ational decision making about screening requires a con-sideration of the balance between benefits and harms.1-4Decisions made on the basis of evidence about benefits
alone are unbalanced and run the risk of causing more harm than
good. Yet evidence about harms is often less available and, when
available, less used than evidence about benefits.5 The lack of in-
formation about harms used in decision making may be partly re-
sponsible for the overuse of some screening tests,6-8 for the lack of
discussion about harms between patients and physicians,9 and for
the large number of “I” statements (for “insufficient evidence”) by
the US Preventive Services Task Force.10
Although this absence of harms evidence in decision making
about screening, whether due to no evidence or to nonuse of avail-
able evidence, has multiple causes, one contributing factor is the lack
of a framework for conceptualizing and organizing our thinking about
harms. A taxonomy of the harms of screening could assist research-
ers and systematic reviewers in asking the right questions, could as-
sist guideline panels in better defining what harms to weigh against
potential benefits, could encourage clinicians to discuss harms with
patients, and could help patients and the public better understand
the real trade-offs inherently involved with screening. We have been
unable to identify a general taxonomy of the harms of screening.
The purpose of this article is to propose a taxonomy to concep-
tualize and define the harms of screening. We present this pro-
posed taxonomy in the hope that it stimulates a discussion leading
to a generally accepted framework.
Methods
We first reasoned that harms are experienced by patients, and thus
the perspective of the taxonomy should be patient centered. We de-
fined harm as any negative effect perceived by patients or signifi-
cant others resulting from screening compared with not screening.
We considered only whether it is reasonable to think that at least
some patients would experience the harm as a negative effect in their
IMPORTANCE Making rational decisions about screening requires information about its harms,
but high-quality evidence is often either not available or not used. One reason may be that we
lack a coherent framework, a taxonomy, for conceptualizing and studying these harms.
OBJECTIVE To create a taxonomy, we categorized harms from several sources: systematic
reviews of screening, other published literature, and informal discussions with clinicians and
patients. We used this information to develop an initial taxonomy and vetted it with local and
national experts, making revisions as needed.
RESULTS We propose a taxonomy with 4 domains of harm from screening: physical effects,
psychological effects, financial strain, and opportunity costs. Harms can occur at any step of
the screening cascade. We provide definitions for each harm domain and illustrate the
taxonomy using the example of screening for lung cancer.
CONCLUSIONS AND RELEVANCE The taxonomy provides a systematic way to conceptualize
harms as experienced by patients. As shown in the lung cancer screening example, the
taxonomy also makes clear where (which domains of harms and which parts of the screening
cascade) we have useful information and where there are gaps in our knowledge. The
taxonomy needs further testing and validation across a broad range of screening programs.
We hope that further development of this taxonomy can improve our thinking about the
harms of screening, thus informing our research, policy making, and decision making with
patients about the wisdom of screening.
JAMA Intern Med. 2014;174(2):281-285. doi:10.1001/jamainternmed.2013.12745
Published online December 9, 2013.
Author Video Interview at
jamainternalmedicine.com




Author Affiliations: Research Center
for Excellence in Clinical Preventive
Services, Cecil G. Sheps Center for
Health Services Research, University
of North Carolina at Chapel Hill (Harris,
Sheridan, Lewis, Barclay, Vu, Kistler,
Golin, DeFrank, Brewer); Department
of Medicine, School of Medicine,
University of North Carolina at Chapel
Hill (Harris, Sheridan, Lewis, Golin);
Department of Family Medicine,
School of Medicine, University of
North Carolina at Chapel Hill (Kistler);
Department of Health Behavior,
Gillings School of Global Public Health,
University of North Carolina at Chapel
Hill (Vu, Golin, DeFrank, Brewer).
Corresponding Author: Russell P.
Harris, MD, MPH, Cecil G. Sheps
Center for Health Services Research,
University of North Carolina, 725
Martin Luther King Blvd, CB7590,
Chapel Hill, NC 27599-7590 (rharris
@med.unc.edu).
Clinical Review & Education
Special Communication | LESS IS MORE
jamainternalmedicine.com JAMA Internal Medicine February 2014 Volume 174, Number 2 281
Copyright 2014 American Medical Association. All rights reserved.
lives, not whether the harm is well documented, frequent, or seri-
ous in medical terms. Harms are “potential” for an individual, since
not everyone experiences them. We defined screening as pertain-
ing to the “screening cascade” (Figure).
We developed an initial taxonomy from several sources: sys-
tematic reviews of screening, our own reviews of published litera-
ture, and informal discussions with both clinicians and patients. We
then vetted the initial taxonomy with multiple groups, including both
local and national experts (see the eAppendix in the Supplement),
making revisions as needed.
Results
Overview
We arrived at a taxonomy of 4 domains: physical harms, psycho-
logical harms, financial strain, and opportunity costs, as defined in
the Table. Although benefits from screening can only occur when
the entire screening cascade is intact, specific harms within the do-
mains occur at different steps throughout the screening cascade
(Figure) and are additive in overall magnitude. We illustrate the tax-
onomy with the example of screening for lung cancer with low-
dose computed tomographic scanning (LDCT), using recent sys-
tematic reviews and our own systematic searches to indicate harms
for which evidence is or is not available.11,12
Physical Harms of LDCT Screening for Lung Cancer
Physical harms occur primarily when we perform a test or proce-
dure or give a treatment to the patient (Figure). For LDCT screen-
ing, the first physical harm is exposure to radiation at the screening
step. An individual undergoing annual screening from age 55 years
to age 79 years could have as many as 25 LDCT scans, with addi-
tional full-dose computed tomographic (CT) scans for positive find-
ings or for surveillance after indeterminate screening results. Over
time, and for a large population, this radiation exposure may add up
to measurable physical harm.13 Although the exact magnitude of this
harm is uncertain, reasonable estimates are available.14
A second physical harm from LDCT screening is in the workup
for a positive screening test result. In the largest LDCT screening trial
(the National Lung Screening Trial [NLST]), 39.1% of people in the
LDCT group had at least 1 positive test result (noncalcified nodule
at least 4 mm in diameter) over 3 annual screening tests; 96.4% of
the positive results were falsely positive.15 Almost all patients with
positive test results had follow-up imaging; 4.2% had a surgical pro-
cedure and 2.2% had a biopsy. Although the rate of serious medical
complications from this workup was low (approximately 1.4%), the
harm associated with the workup goes beyond medical complica-
tions. The physical discomfort of having the workup is also a harm,
regardless of whether there is a complication. It is also of note that
almost twice as many NLST participants in the screening arm expe-
rienced a serious complication from the workup as had their lives
extended by screening.15 The percentage of people having a seri-
ous complication from the workup of a positive LDCT result will likely
be greater in settings outside of a clinical trial.16 We found no re-
search evidence on the magnitude or “burden” of the physical harm
that patients associate with having these workup procedures, with
or without complications.
The third category of physical harm from screening is associ-
ated with treatment: either earlier treatment of a person with can-
cer that would have been found later without screening or over-
treatment of a person with cancer that would not have been found
without screening. As screening and earlier treatment delays death
for only 20% of patients destined to die from lung cancer,11 80% of
screened people with fatal cancer will die at the same time they
would have without screening. Early detection from screening has
caused these patients to live longer with the diagnosis, receiving
treatment and follow-up for a longer time. They experience harm
rather than benefit from screening. For patients with cancer that
would not have become clinically important, screening leads to un-
necessary treatment harms. Our best evidence shows that approxi-
Figure. The Screening Cascade
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mately 20% to 25% of people with lung cancers diagnosed via
screening17-19 are overdiagnosed and at risk of overtreatment.
Psychological Harms of LDCT Screening for Lung Cancer
Psychological harms of screening may occur at any of the steps of
the screening cascade (Figure) but are especially salient at steps
when people are given new information, such as receiving results
of screening tests or workup. Overall, we found 13 publications from
11 studies,20-32 all with varying limitations, that examined some as-
pect of the psychological harms of the screening cascade for lung
cancer. Anticipation of having a screening test is stressful for some
patients.20,27,32 Another stressful period is after the screening test
before the patient receives the results.29
As noted in the previous subsection, 39% of participants in the
NLST had at least 1 positive screening test result, with a noncalci-
fied nodule at least 4 mm in diameter. Many of these patients will
have a nodule between 4 mm and 8 mm in diameter, an “indeter-
minate” category; recommendations are for these patients to un-
dergo periodic repeated imaging to ascertain whether the nodule
is growing.33 This system of surveillance puts the patient (and their
significant others) in an uncertain state for a prolonged period. We
found no research exploring this harm for LDCT screening.
Some patients develop increased anxiety after receiving a posi-
tive or indeterminate screening result, although these anxiety lev-
els may decline with time.22,24,30,31,34 A larger number of patients
experience other psychological harms, such as condition-specific dis-
tress, as thoughts of having lung cancer lead to sleepless nights, in-
trusive thoughts, and worries about the future.21,27 We found only
3 studies that assessed condition-specific distress.21,24,27
Overlaying the psychological harms is the context of the screen-
ing situation. In the case of LDCT screening for lung cancer, eligible
people, according to the draft US Preventive Services Task Force
recommendations,14 have at least 30 pack-years of smoking his-
tory. To the extent that these people see themselves as having a so-
cially unacceptable personal behavior that may have caused lung can-
cer, they may experience feelings of guilt, shame, and anxiety in
anticipation of possibly being diagnosed with lung cancer.21,35 We
found no studies that examined this issue for LDCT screening.
Another psychological harm from screening is the effect on in-
dividuals of receiving a diagnosis of lung cancer. Although we found
little research documenting this effect,28,36 it is likely that “label-
ing” the individual in this way plays a major role in how the indi-
vidual thinks of himself or herself in the future. Labeling is due to
screening in the 2 aforementioned situations: earlier detection of fa-
tal cancers for which treatment is ineffective, and overdiagnosis of
cancers that would not have caused the patient important health
problems. In both situations, screening has caused psychological
harm by labeling patients with a potentially fatal diagnosis. Al-
though one can estimate the frequency of these situations, we found
no studies of the psychological “burden” of labeling as experienced
by patients.
Still another group of patients with an abnormal screening test
result who may feel the psychological effects of a workup are those
with “incidental” findings on screening CT, findings not indicative of
lung cancer but that may indicate some other medical condition. In
the NLST trial, more than 10% of all people screened had incidental
findings on the first LDCT screen, and approximately 6% had an in-
cidental finding on both screening rounds 2 and 3.15,37 Still more
people undergoing a workup for lung cancer may have an inciden-
tal finding from more intense imaging. Patients with incidental find-
ings often go through a different type of workup, including some-
times invasive procedures, than that for lung cancer (Figure).
Although some have tried to make the case that these incidental find-
ings could be beneficial, it is much more likely that their overall ef-
fect is negative. The burden of proof for any benefit for these inci-
dental findings lies with those proposing the benefit. We found no
studies examining the psychological (or physical) effects of workup
of incidental findings and discovery of incidental disease.
Finally, there are psychological harms of nonbeneficial treat-
ment due to screening. As noted previously, this occurs with inef-
fective earlier treatment, with overtreatment in overdiagnosed pa-
tients, and in patients undergoing ineffective treatment for an
incidental condition found by screening or workup. These treat-
ments can include major surgery, radiation, and chemotherapy, all
associated with known psychological harms.25,26 The fact that these
patients do not know that the harm they are experiencing is unnec-
essary does not reduce the magnitude of their suffering.
Financial Strain of LDCT Screening for Lung Cancer
Financial strain from screening comes not only from actual finan-
cial charges for the screening test, but also from concern about the
anticipated financial cost of being diagnosed with and treated for
lung cancer. Financial strain may start with the screening test itself
and then increase with a positive result and anticipation of the cost
of the workup. The patient often does not know ahead of time ex-
actly what the cost will be and may expect the worst-case scenario.
If the workup finds lung cancer, financial strain may encompass fu-
ture lost wages and the effects on one’s family. Previous financial
plans may be thrown into disarray. We found no studies examining
this type of harm.
Table. Taxonomy of the Harms of Screening: Domains and Definitions
Domain and Definition Can occur…
Physical harms: Physical
problems, including discomfort,
perceived by the patient or
significant others
When something is done to a patient, such
as a screening test, workup procedures, or
treatment. Usually does not result from
receiving information, such as screening
test results; an exception would be if such
information led to suicide or other
self-harm. Harm goes beyond medical





perceived by the patient or
significant others
At any step of the screening cascade.
Includes effects of anticipation of
discomfort from a procedure or from what
might be found by a screening test or
workup; reactions to results received from
screening test or workup; effects of a
positive screening test or “labeling” from
receiving a diagnosis; and psychological
effects of ineffective or unnecessary
treatment due to screening.
Financial strain: Concern and
relationship strain due to
thinking about possible or actual
financial consequences of
screening and the potential of
being diagnosed with a disease
At any step of the screening cascade. Can
result from anticipated or real costs due to
the cascade, plus the financial
consequences of missing work or other
expenses related to screening. Includes
disruption of previous financial plans.
Opportunity cost: Activities
forgone because of time, effort,
and resources required to
participate in the screening
cascade
At any step of the screening cascade.
Includes distraction from other
health-related activities or self-care, such
as exercise or seeking care for other health
problems, as well as reduced time or
energy for other important or meaningful
activities. Not the same as cost of medical
care or cost-effectiveness.
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Opportunity Costs of LDCT Screening for Lung Cancer
People undergoing LDCT screening and workup may experience
harm through missed opportunities. Some of these missed oppor-
tunities have to do with health, including distraction from other im-
portant healthy activities or visits to clinicians for important health
problems. Other missed opportunities may include time with friends
and family. Finally, there is the missed opportunity of continuing prog-
ress at work and on one’s own projects. We found no research evi-
dence about this type of harm.
Discussion
The taxonomy encourages a systematic approach to thinking about
harms, an approach that is needed to move research, discussion, and
decision making about screening from an overemphasis on ben-
efits alone to a focus on balancing benefits and harms.1
There are limitations to our approach. One criticism we have en-
countered is that our taxonomy overstates the importance of psy-
chological harms. It is not our intention, however, to prioritize one
type of harm over another. The effect of a particular harm on a
screened population depends on the frequency of the harm as well
as its burden for the individuals affected. By making sure that psy-
chological effects are considered along with physical effects, we as-
sert that both domains of harms are worthy of being considered in
screening decisions.
Some have questioned our inclusion of financial strain under the
rubric of “harms.” For real people, however, the strain of antici-
pated financial problems can be important in weighing the deci-
sion whether to be screened. We believe it is easier to conceptual-
ize financial strain alongside of but separate from other harms. We
also distinguish “opportunity costs” from financial strain. By oppor-
tunity costs we do not mean financial costs but rather the loss of al-
ternative activities that could have benefited the patient in mul-
tiple ways. Part of opportunity costs comes from the time required
to participate in the screening cascade. Another part comes from
the distraction of screening from other activities, both in terms of
health and enjoyment of life.
Some clinicians have commented to us that harms are just the
price we pay for the benefits of screening. It may be, however, that
were we to fully appreciate the frequency and burden of harms, our
enthusiasm for screening would decline. The taxonomy is de-
signed to unveil the true extent of the problem of harms.
Finally, there are still further harms to be considered. For in-
stance, another harm from screening is the strain on the medical care
system. Organizing systematic screening requires careful planning
and effort, including changing staff roles, increasing patient educa-
tion, taking clinicians’ time, working out referral patterns and follow-
up, considering outreach, and changing documentation. Inevita-
bly, such effort directed to screening means less effort directed
toward other health issues. We have not captured this type of harm
in our taxonomy.
A second type of harm that is not in our taxonomy is undermin-
ing a culture of wellness. That is, widespread screening sends the
message to the public that we all have undiscovered health prob-
lems, that we are all “at risk,” “unwell” in ways we do not even know.
This has the potential to steadily degrade society’s sense of its own
health, with uncertain but probably negative implications for the way
we live. If we were to take potential harms more into consideration
in deciding about and promoting screening, we might limit screen-
ing to more targeted situations, perhaps reducing these negative so-
cial effects.
An earlier version of our taxonomy included the category of
“hassles.” We dropped this category because of the complaint
that the word trivializes the concept and undermines the impor-
tance of harms. We remain impressed, however, by the difficul-
ties many patients have in organizing their lives for the some-
times complex requirements of going through the screening
cascade.
To some extent, any such taxonomy as ours is arbitrary; the ques-
tion is whether it is useful in developing better research evidence
and in improving discussions and decision making about screen-
ing. In applying our taxonomy to the current issue of lung cancer
screening, we were struck by 2 observations. The first is that lung
cancer screening can cause harm in multiple ways. The second is that,
for many of these harms, we have little or no high-certainty evi-
dence about the burden they cause to patients. For example, we
know that positive test results (usually falsely positive) are com-
mon, but we have insufficient evidence about the full range of psy-
chological harms (condition specific as well as generalized distress),38
the opportunity costs, and the financial strain that these positive re-
sults, as well as incidental findings, cause. We have insufficient evi-
dence about the burden caused by the physical discomfort of the
multiple workup procedures and little evidence about the psycho-
logical harm caused by surveillance of indeterminate nodules. In ad-
dition, we have scant information about the psychological burden
due to labeling and treating people for lung cancer with ineffective
or unnecessary treatment. It is difficult to see how clear recommen-
dations for LDCT screening for lung cancer can be made before these
harms are more completely understood.
Conclusions
Our purpose in developing a taxonomy of the potential harms of
screening is to help investigators, policy makers, clinicians, and the
public think more clearly and systematically about harms and to con-
sider harms equally with benefits in decisions about screening. We
do not assert that harms always outweigh benefits, only that it is al-
ways necessary to weigh the two. We consider this a draft tax-
onomy, a work in progress that could contribute to our current pub-
lic discussion about screening. In the end, we hope that a widely
agreed-on taxonomy will eventually lead to more balanced deci-
sion making about the wisdom of screening.
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